Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
21/11/2024 | 00:25 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:BLTE | Belite Bio Inc |
12/11/2024 | 07:00 | GlobeNewswire Inc. | Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | NASDAQ:BLTE | Belite Bio Inc |
05/11/2024 | 14:00 | GlobeNewswire Inc. | Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results | NASDAQ:BLTE | Belite Bio Inc |
04/11/2024 | 12:02 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLTE | Belite Bio Inc |
03/11/2024 | 22:00 | GlobeNewswire Inc. | Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds | NASDAQ:BLTE | Belite Bio Inc |
14/10/2024 | 14:00 | GlobeNewswire Inc. | Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting | NASDAQ:BLTE | Belite Bio Inc |
08/10/2024 | 23:48 | Edgar (US Regulatory) | Form 144/A - Report of proposed sale of securities: [Amend] | NASDAQ:BLTE | Belite Bio Inc |
08/10/2024 | 14:00 | GlobeNewswire Inc. | Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit | NASDAQ:BLTE | Belite Bio Inc |
01/10/2024 | 12:03 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:BLTE | Belite Bio Inc |
26/09/2024 | 14:51 | GlobeNewswire Inc. | Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing | NASDAQ:BLTE | Belite Bio Inc |
17/09/2024 | 17:22 | GlobeNewswire Inc. | International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 | NASDAQ:BLTE | Belite Bio Inc |
10/09/2024 | 14:00 | GlobeNewswire Inc. | Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease | NASDAQ:BLTE | Belite Bio Inc |
03/09/2024 | 14:00 | GlobeNewswire Inc. | Belite Bio to Participate in Three Upcoming Investor Conferences | NASDAQ:BLTE | Belite Bio Inc |
01/09/2024 | 14:00 | GlobeNewswire Inc. | Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer | NASDAQ:BLTE | Belite Bio Inc |
09/08/2024 | 22:30 | GlobeNewswire Inc. | Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update | NASDAQ:BLTE | Belite Bio Inc |
08/08/2024 | 14:00 | GlobeNewswire Inc. | Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference | NASDAQ:BLTE | Belite Bio Inc |
06/08/2024 | 01:10 | GlobeNewswire Inc. | Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results | NASDAQ:BLTE | Belite Bio Inc |
08/07/2024 | 14:00 | GlobeNewswire Inc. | Belite Bio to Present at the JonesHealthcare Seaside Summit | NASDAQ:BLTE | Belite Bio Inc |
12/06/2024 | 08:55 | GlobeNewswire Inc. | Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan | NASDAQ:BLTE | Belite Bio Inc |
14/05/2024 | 14:00 | GlobeNewswire Inc. | Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference | NASDAQ:BLTE | Belite Bio Inc |
14/05/2024 | 03:50 | GlobeNewswire Inc. | Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:BLTE | Belite Bio Inc |
13/05/2024 | 14:00 | GlobeNewswire Inc. | Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference | NASDAQ:BLTE | Belite Bio Inc |
08/05/2024 | 14:00 | GlobeNewswire Inc. | Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results | NASDAQ:BLTE | Belite Bio Inc |
06/05/2024 | 14:15 | GlobeNewswire Inc. | Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant | NASDAQ:BLTE | Belite Bio Inc |
06/05/2024 | 14:00 | GlobeNewswire Inc. | Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting | NASDAQ:BLTE | Belite Bio Inc |
01/05/2024 | 22:15 | GlobeNewswire Inc. | Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting | NASDAQ:BLTE | Belite Bio Inc |
26/04/2024 | 01:15 | GlobeNewswire Inc. | Belite Bio Announces $25 Million Registered Direct Offering | NASDAQ:BLTE | Belite Bio Inc |
22/03/2024 | 13:00 | GlobeNewswire Inc. | Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan | NASDAQ:BLTE | Belite Bio Inc |
12/03/2024 | 03:28 | GlobeNewswire Inc. | Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website | NASDAQ:BLTE | Belite Bio Inc |
12/03/2024 | 02:27 | GlobeNewswire Inc. | Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | NASDAQ:BLTE | Belite Bio Inc |